Clinical trial · Observational
Disease Outcomes and Toxicities in Patients With Gastrointestinal and Sarcomatous Malignancies
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This prospective, single-institution, observational study explores disease outcomes and toxicities in subjects with gastrointestinal malignancies and sarcoma (bone and soft tissue) who are being treated with standard-of-care therapies including radiotherapy. Recent advances in treatment approaches affected disease outcomes and toxicities. Prospective monitoring of disease outcomes and toxicities using standardized assessments will provide information about recent changes in the standard of care and further refine treatment approaches and prospective clinical trial design.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastrointestinal Cancer | Malignant Digestive System Neoplasm | ALIAS | 0.90 |
| Sarcoma | Sarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Survey | Other | — | UNRESOLVED |
| Toxicity Assessments | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Single Arm
- description
- Subjects who are with gastrointestinal malignancies or sarcoma receive radiotherapy.
- interventionNames
- Other: Survey
- Other: Toxicity Assessments
Primary outcomes (1)
- measure
- Disease-free survival
- timeFrame
- Up to 10 years
- description
- Disease-free survival is defined as the length of time after treatment in which the subject survives with no signs or symptoms of cancer.
Secondary outcomes (5)
- measure
- Local Control
- timeFrame
- Up to 10 years
- description
- Local Control is defined as radiographic and clinical assessments determined by the patient's treating physician.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria In order to participate in this study a subject must meet all of the eligibility criteria outlined below. 1. Subject is willing and able to provide written informed consent to participate in the study and HIPAA authorization for the release of personal health information. Subjects are willing and able to comply with study procedures based on the judgment of the investigator or protocol designer. 2. Age ≥ 18 years at the time of consent. 3. Histological, cytological, or radiographic evidence/confirmation of a gastrointestinal malignancy or sarcoma. 4. Females with childbearing potential and male subjects with fathering potential are allowed to participate in this study. Exclusion Criteria All subjects meeting any exclusion criteria at baseline will be excluded from study participation. 1. Inability or unwillingness to provide informed consent 2. Patients who state they do not expect to be available or willing to follow up at expected intervals post-treatment
References
Publications (0)
Data not yet available